About the role of indacaterol in obstructive airways disorder: pro Report as inadecuate

About the role of indacaterol in obstructive airways disorder: pro - Download this document for free, or read online. Document in PDF available to download.

Revista Portuguesa de Pneumología 2012, 18 1

Author: M. Drummond

Source: http://www.redalyc.org/


Revista Portuguesa de Pneumología ISSN: 0873-2159 sppneumologia@mail.telepac.pt Sociedade Portuguesa de Pneumologia Portugal Drummond, M. About the role of indacaterol in obstructive airways disorder: PRO Revista Portuguesa de Pneumología, vol.
18, núm.
1, enero-febrero, 2012, pp.
5-7 Sociedade Portuguesa de Pneumologia Lisboa, Portugal Available in: http:--www.redalyc.org-articulo.oa?id=169724478003 How to cite Complete issue More information about this article Journals homepage in redalyc.org Scientific Information System Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Non-profit academic project, developed under the open access initiative Document downloaded from http:--www.elsevier.pt, day 28-03-2012.
This copy is for personal use.
Any transmission of this document by any media or format is strictly prohibited. Rev Port Pneumol.
2012;18(1):5---7 www.revportpneumol.org EDITORIAL About the role of indacaterol in obstructive airways disorder: PRO夽 A propósito do papel do Indacaterol na patologia obstrutiva das vias aéreas: PRÓ Chronic Obstructive Pulmonary Disease (COPD) is a major cause of mortality and chronic morbidity throughout the world.1 COPD is nowadays the fourth leading cause of death2 and its mortality is estimated to increase in the coming decades.3 Most studies have indicated that the existing pharmacologic treatment for COPD do not modify the long-term decline of pulmonary function,4,5 so pharmacotherapy is mainly used to decrease symptoms and-or complications.1 Bronchodilator medications are central to the symptomatic management of COPD and ␤2 agonists are recommended in all stages of severity of COPD.1 As with all chronic diseases, non-adherence to treatment is common in patients with COPD.6 More complex regimens generally result in suboptimal adherence, with dosing and the absence of immediate effect on symptoms regarded as the principal factors negatively influencing adherence.7 Indacater...

Related documents